Understanding how SIRT1 affects aggressive breast cancer
Elucidating the tumor suppressive effects of the sirtuin, SIRT1, in triple-negative breast cancer
This study is looking at a protein called SIRT1 to see how it affects the growth and spread of triple-negative breast cancer, with the hope that understanding this could help find better treatments for patients facing this tough type of cancer.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cornell University NIH-funded |
| Lab location | 1 site (Ithaca, United States) |
| Project ID | NIH-10918287 on NIH RePORTER |
What this research studies
This research investigates the role of SIRT1, a protein that may act as a tumor suppressor, in triple-negative breast cancer (TNBC), which is known for its aggressive nature and poor prognosis. The study aims to explore how reducing SIRT1 levels in TNBC cells influences tumor growth and metastasis using mouse models. By examining the mechanisms behind SIRT1 regulation, the research seeks to uncover new pathways that contribute to the aggressiveness of TNBC, potentially leading to better treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who are seeking innovative treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who are not diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches for treating triple-negative breast cancer, improving outcomes for patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of SIRT1 in cancer, indicating that this approach may yield valuable insights.
Where this research is happening
Ithaca, United States
- Cornell University — Ithaca, United States (Active)
Researchers
- Principal investigator: Mullmann, James — Cornell University
- Study coordinator: Mullmann, James
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.